Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLO9FU)

• Drug Name: Fluo-3 Drug Info
• Synonyms: 121714-13-4; 123632-39-3; 23D4W0B50Y; AC1L2XTQ; AKOS015894386; C11369; CHEBI:5107; CHEMBL509919; CTK8F0793; Fluo 3; Fluo-3; Fluo-3, suitable for fluorescence, ~70%; Fluo-3-AM; Glycine,N-[2-[2-[2-[bis(carboxymethyl)amino]-5-(2,7-dichloro-6-hydroxy-3-oxo-3H-xanthen-9-yl)phenoxy]ethoxy]-4-methylphenyl]-N-(carboxymethyl)-; OZLGRUXZXMRXGP-UHFFFAOYSA-N; SCHEMBL28109; UNII-23D4W0B50Y; ZINC8295051

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative

• Cross-matching ID:
  PubChem CID: 104978
  ChEBI ID: ChEBI:5107
  CAS Number: CAS 123632-39-3
  TTD Drug ID: DMLO9FU
  VARIDT Drug ID: DR00344

Molecule-Related Drug Atlas

Drug(s) Transported By Multidrug resistance-associated protein 1 (ABCC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[4]
Folic acid	DMEMBJC	Folate-deficiency anemia	3A02.Y	Approved	[5]
Cisplatin	DMRHGI9	Solid tumour/cancer	2A00-2F9Z	Approved	[6]
Etoposide	DMNH3PG	Solid tumour/cancer	2A00-2F9Z	Approved	[7]
Verapamil	DMA7PEW	Hypertension	BA00-BA04	Approved	[8]
Irinotecan	DMP6SC2	Colorectal cancer	2B91.Z	Approved	[9]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[10]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[11]
Daunorubicin	DMQUSBT	Acute myeloid leukaemia	2A60	Approved	[12]

Drug(s) Transported By Organic anion transporting polypeptide 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[13]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[14]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[15]
Etoposide	DMNH3PG	Solid tumour/cancer	2A00-2F9Z	Approved	[16]
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[15]
Pravastatin	DM6A0X7	Hypercholesterolaemia	5C80.0	Approved	[17]
Mycophenolate mofetil	DMPQAGE	Organ transplant rejection	NE84	Approved	[18]
Atorvastatin	DMF28YC	Cardiovascular disease	BA00-BE2Z	Approved	[19]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[20]
Pitavastatin calcium	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[17]

Drug(s) Transported By Organic anion transporting polypeptide 1B3 (SLCO1B3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[21]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[15]
Etoposide	DMNH3PG	Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Diclofenac	DMPIHLS	Osteoarthritis	FA00-FA05	Approved	[22]
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[15]
Pravastatin	DM6A0X7	Hypercholesterolaemia	5C80.0	Approved	[23]
Mycophenolate mofetil	DMPQAGE	Organ transplant rejection	NE84	Approved	[18]
Atorvastatin	DMF28YC	Cardiovascular disease	BA00-BE2Z	Approved	[20]
Erythromycin	DM4K7GQ	Bacterial infection	1A00-1C4Z	Approved	[24]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[20]

Molecular Interaction Atlas of This Drug

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[1]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[2]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[2]

References

• [1] Export pumps for anionic conjugates encoded by MRP genes. Adv Enzyme Regul. 1999;39:237-46.
• [2] Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
• [3] The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
• [4] Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
• [5] Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
• [6] Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
• [7] Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
• [8] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [9] ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
• [10] Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
• [11] Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
• [12] Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
• [13] Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
• [14] Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
• [15] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [16] Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
• [17] The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
• [18] Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
• [19] Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
• [20] FDA Drug Development and Drug Interactions
• [21] LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
• [22] Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
• [23] Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
• [24] Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.